Sentences with phrase «high tumor burden»
Indeed, the authors point out that Ipilimumab might better effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups including those with high tumor burden.
https://www.sciencedaily.com/
However, he noted that there was a tendency to treat patients with higher tumor burdens (> 5 % blasts), and outcomes in this setting are less than optimal.
[18] Clearly, the higher tumor burden at baseline in stage IV patients adversely affected responses.
Not exact matches
«The good news is that we discovered that a subset of patients who had both high tumor mutation burden and high PDL - 1 positive status did experience a significant benefit from immunotherapy,» says Carbone.
Patients with both high tumor mutation burden and high PDL - 1 positive status had a 75 percent response rate compared with a 16 percent response rate to immunotherapy among patients with low mutation burden and low PDL - 1.
«Given the high discrepancy of genetic findings between a primary tumor and metastatic sites within the same patient, our study suggests we should concentrate on metastatic sites that represent the majority of the tumor burden.
ETP - ALL tumors exhibit an unusually high burden of DNA copy number alterations, but no unifying genetic have been identified.
Positron emission tomography (PET) imaging of metabolic tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.
«Both total metabolic tumor volume (TMTV), computed on baseline PET, and end - of - induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor - burden follicular lymphoma,» reported lead author Anne Ségolène Cottereau, MD, from Cochin Hospital, René Descartes University, Paris, France, and colleagues.